These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2477816)

  • 21. Possible contribution of encainide metabolites to the long-term antiarrhythmic efficacy of encainide.
    Winkle RA; Peters F; Kates RE; Harrison DC
    Am J Cardiol; 1983 Apr; 51(7):1182-8. PubMed ID: 6404150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of incessant supraventricular tachycardia by intravenous and oral encainide.
    Brugada P; Abdollah H; Wellens HJ
    J Am Coll Cardiol; 1984 Dec; 4(6):1255-60. PubMed ID: 6438205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Encainide. A review of its pharmacological properties and therapeutic efficacy.
    Brogden RN; Todd PA
    Drugs; 1987 Nov; 34(5):519-38. PubMed ID: 3121275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sinus bradycardia and multiple episodes of sinus arrest following administration of ibutilide.
    Amin NB; Borzak S; Housholder S; Tisdale JE
    Heart; 1998 Jun; 79(6):628-9. PubMed ID: 10078099
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of encainide proarrhythmia with hypertonic saline.
    Gardner ML; Brett-Smith H; Batsford WP
    Pacing Clin Electrophysiol; 1990 Oct; 13(10):1232-5. PubMed ID: 1701536
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the effects of placebo and encainide on programmed electrical stimulation and ventricular arrhythmia frequency.
    Duff HJ; Roden DM; Dawson AK; Oates JA; Smith RF; Woosley RL
    Am J Cardiol; 1982 Aug; 50(2):305-12. PubMed ID: 6808820
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical electrophysiologic effects of encainide, a newly developed antiarrhythmic agent.
    Sami M; Mason JW; Peters F; Harrison DC
    Am J Cardiol; 1979 Sep; 44(3):526-32. PubMed ID: 474433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Electrophysiological effects of encainide in man].
    Cassagneau B; Calazel J; Puel J; Massabuau P; Miquel JP; Bounhoure JP; Marin T; Narula OS
    Arch Mal Coeur Vaiss; 1984 Jun; 77(6):707-11. PubMed ID: 6431937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative study of encainide and quinidine in the treatment of ventricular arrhythmias.
    Morganroth J; Somberg JC; Pool PE; Hsu PH; Lee IK; Durkee J; Salerno DM
    J Am Coll Cardiol; 1986 Jan; 7(1):9-16. PubMed ID: 3079781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spectrum of antiarrhythmic response to encainide.
    Duff HJ; Roden DM; Carey EL; Wang T; Primm RK; Woosley RL
    Am J Cardiol; 1985 Nov; 56(13):887-91. PubMed ID: 3933319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative study of encainide and disopyramide in chronic ventricular arrhythmias: a double-blind placebo-controlled crossover study.
    Caron JF; Libersa CC; Kher AR; Kacet S; Wanszelbaum H; Dupuis BA; Poirier JM; Lekieffre JP
    J Am Coll Cardiol; 1985 Jun; 5(6):1457-63. PubMed ID: 2582017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Electrophysiologic and electrocardiographic effects, efficacy and safety of encainide in malignant ventricular arrhythmias associated with coronary artery disease.
    Weintraub AR; Manolis AS; Estes NA
    Am J Cardiol; 1990 Oct; 66(12):947-53. PubMed ID: 2121017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electrophysiologic effects, efficacy and tolerance of class Ic antiarrhythmic agents in Wolff-Parkinson-White syndrome.
    Manolis AS; Salem DN; Estes NA
    Am J Cardiol; 1989 Mar; 63(11):746-50. PubMed ID: 2493734
    [No Abstract]   [Full Text] [Related]  

  • 34. Long-term efficacy of oral encainide in frequent and repetitive ventricular arrhythmias.
    Bongiorni MG; Levorato D; Arlotta C; Paperini L; Contini C
    Eur Heart J; 1988 Jul; 9(7):765-76. PubMed ID: 3139413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical use of class IC antiarrhythmic drugs.
    Abi Samra F
    J La State Med Soc; 1989 May; 141(5):27-31. PubMed ID: 2499646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia.
    Kuck KH; Kunze KP; Schlüter M; Duckeck W
    Am J Cardiol; 1988 Dec; 62(19):37L-44L. PubMed ID: 3144166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
    Akiyama T; Pawitan Y; Greenberg H; Kuo CS; Reynolds-Haertle RA
    Am J Cardiol; 1991 Dec; 68(17):1551-5. PubMed ID: 1720917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electrophysiology of oral encainide.
    Jackman WM; Zipes DP; Naccarelli GV; Rinkenberger RL; Heger JJ; Prystowsky EN
    Am J Cardiol; 1982 Apr; 49(5):1270-8. PubMed ID: 6801954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of twice daily with thrice daily administered encainide for benign or potentially lethal ventricular arrhythmias.
    Hohnloser SH; Zabel M; Zehender M; Meinertz T; Just H
    Am J Cardiol; 1989 Jan; 63(1):73-6. PubMed ID: 2462343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
    Cardiac Arrhythmia Pilot Study (CAPS) Investigators
    Am J Cardiol; 1988 Mar; 61(8):501-9. PubMed ID: 2894169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.